Evidence map›Paper›PMID 41688666›Full record

ArticleScientific reports2026

Design of a multiepitope immunotherapy for fish allergy.

Abdelfateh Chourir, Hafs Essaadi, Farah Makhloufi, Aya Abidou, Ouissal Hachlaf, Zineb Lafi, Boutaina Elgharbaoui, Mohammed Hakmi, Rachid Eljaoudi, Naima El Hafidi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Abdelfateh ChourirPediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Hafs EssaadiPediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Farah MakhloufiPediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Aya AbidouPediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Ouissal HachlafPediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Zineb LafiPediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Boutaina ElgharbaouiPediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
Mohammed HakmiMohammed VI Center for Research and Innovation, Rabat, Morocco.
Rachid EljaoudiBiotechnology Lab (MedBiotech) Bioinova Research Center, Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco.
Naima El HafidiPediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco. n.elhafidi@um5r.ac.ma.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fish allergy is a significant global health concern and often leads to persistent and potentially severe hypersensitivity reactions. The molecular heterogeneity of fish allergens poses challenges for developing broadly applicable immunotherapies. In this study, an integrated immunoinformatics pipeline was used to design a multi-epitope vaccine construct targeting three major fish allergens: parvalbumin, enolase, and aldolase. Predicted B-cell and T-cell epitopes were screened for immunogenicity, non-allergenicity, and lack of toxicity, and the selected peptides were assembled into a 432-amino acid chimeric construct using rationally chosen linkers to facilitate antigen processing. Computational analyses predicted the construct to exhibit favorable physicochemical properties, including stability, solubility, and a broad theoretical population coverage. Docking and molecular dynamics simulations suggested a potential interaction with Toll-like receptor 4, offering preliminary insight into possible innate immune engagement. As these findings are entirely in silico, they represent a theoretical framework; experimental validation is necessary to determine the construct's biological behavior, safety, and immunological relevance.

Indexed as

AllergensEpitopesEpitopes, T-LymphocyteFishesFood HypersensitivityImmunotherapyAnimalsEpitopes, B-LymphocyteFish ProteinsFructose-Bisphosphate AldolaseHumansImmunoinformaticsMolecular Docking SimulationMolecular Dynamics SimulationParvalbuminsProtein Subunit VaccinesAllergensEpitopesEpitopes, B-LymphocyteEpitopes, T-LymphocyteFish ProteinsFructose-Bisphosphate AldolaseParvalbuminsProtein Subunit VaccinesEpitope predictionFish allergyImmunoinformaticsMulti-epitope vaccineReverse vaccinology

Identifiers

PMID41688666
PMCPMC12982822

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.